1-[2-[1-ethyl-3-(1H-pyrazol-4-yl)pyrrolo[2,3-c]pyridin-5-yl]ethynyl]cyclopentan-1-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 1-[2-[1-ethyl-3-(1H-pyrazol-4-yl)pyrrolo[2,3-c]pyridin-5-yl]ethynyl]cyclopentan-1-ol
• 化学式: C₁₉H₂₀N₄O
• 分子量: 320.4
• InChiKey: MPHNXUKZXHHZPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  66.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE 3-(1BH-PYRAZOL-4-YL)-1H-PYRROLO[2,3-C]PYRIDINE EN TANT QU'INHIBITEURS DE LA NIK
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2015044269A1

  公开（公告）日：2015-04-02

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK -also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disordersand autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.

  本发明涉及对哺乳动物在治疗和/或预防方面有用的药物，特别是对NF-κB诱导激酶（NIK - 也称为MAP3K14）的抑制剂，用于治疗癌症、炎症性疾病、代谢性疾病和自身免疫性疾病等疾病。该发明还涉及包含这些化合物的药物组合物，制备这些化合物和组合物的过程，以及利用这些化合物或药物组合物预防或治疗癌症、炎症性疾病、代谢性疾病（包括肥胖和糖尿病）和自身免疫性疾病。
• NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP3049412B1

  公开（公告）日：2017-07-12
• NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-c]PYRIDINE DERIVATIVES AS NIK INHIBITORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20160229851A1

  公开（公告）日：2016-08-11

  The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-κB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
• US9981963B2
  申请人：——

  公开号：US9981963B2

  公开（公告）日：2018-05-29